MPN stands for myeloproliferative neoplasm, a group of blood cancers in which the bone marrow produces too many of one or more types of blood cells. Unlike many cancers that form tumors, MPNs cause problems by flooding the bloodstream with excess red blood cells, white blood cells, or platelets, leading to complications like blood clots, enlarged organs, and progressive scarring of the bone marrow. MPNs are chronic conditions, meaning they develop slowly and are managed over years or even decades.
The Main Types of MPN
There are several diseases grouped under the MPN umbrella. The three most common are polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). Each one involves overproduction of a different blood cell type, and each carries its own risks and trajectory.
Polycythemia vera is driven by an overproduction of red blood cells. The blood becomes thicker than normal, which raises the risk of clots, strokes, and heart attacks. It’s typically flagged when routine blood work shows a hematocrit level above 49% in men or 48% in women.
Essential thrombocythemia involves too many platelets, the tiny cell fragments responsible for clotting. A platelet count at or above 450,000 per microliter (normal is roughly 150,000 to 400,000) is one of the diagnostic markers. Many people with ET feel fine for years, but the excess platelets can paradoxically cause both abnormal clotting and, at very high counts, bleeding.
Primary myelofibrosis is the most serious of the three. The bone marrow gradually replaces its normal, blood-producing tissue with scar tissue (fibrosis). As the marrow fails, blood cell production shifts to the spleen and liver, causing them to enlarge, sometimes dramatically. Fibrosis is graded on a scale from 0 (normal marrow) to 3 (dense collagen scarring with bone changes).
Less common MPNs include chronic myeloid leukemia (CML), chronic neutrophilic leukemia, and chronic eosinophilic leukemia. CML is often discussed separately because it has its own highly effective targeted treatment.
What Causes an MPN
Nearly all MPNs are caused by acquired genetic mutations, meaning they develop during a person’s lifetime rather than being inherited from a parent. The mutations occur in blood-forming stem cells in the bone marrow and cause those cells to grow in an uncontrolled way.
The most well-known mutation is in the JAK2 gene. It’s found in roughly 95% of people with polycythemia vera and around 40 to 60% of those with essential thrombocythemia or myelofibrosis. Two other mutations, in the CALR and MPL genes, account for most of the remaining cases of ET and PMF. About 10 to 15% of ET and PMF patients have none of these three mutations, a group sometimes called “triple-negative.”
All three mutations ultimately activate the same signaling pathway, a cellular switch called JAK-STAT that tells blood cells to keep dividing. This shared biology is why treatments that block JAK signaling work across different MPN types.
Symptoms and Daily Impact
MPNs are sometimes discovered by accident on routine blood work, before any symptoms appear. When symptoms do develop, they can be surprisingly varied and easy to dismiss as normal aging or stress.
Doctors track MPN symptom burden using a standardized ten-item scale. The symptoms it measures give a good picture of what living with an MPN actually feels like: fatigue (the most common and often most disabling), difficulty concentrating, early fullness when eating, inactivity, night sweats, itching, bone pain, abdominal discomfort, unintended weight loss, and fevers. Each is rated on a 0 to 10 scale, and the total score helps guide treatment decisions.
Fatigue in MPNs is not ordinary tiredness. Many patients describe it as a bone-deep exhaustion that doesn’t improve with rest. Itching, particularly after a warm shower, is a hallmark of polycythemia vera. Abdominal discomfort and early fullness typically come from an enlarged spleen pressing on the stomach.
Blood Clots: The Major Risk
The most dangerous complication of MPNs is thrombosis, or abnormal blood clotting. Nearly 10% of MPN patients already have a clotting event at or around the time of diagnosis. Compared to the general population, MPN patients face roughly three times the risk of arterial clots (including stroke and heart attack) in the months after diagnosis, and nearly ten times the risk of venous clots like deep vein thrombosis or pulmonary embolism.
Those elevated risks decrease over time but never fully normalize. At five years, the risk of arterial clots is still about 1.5 times higher than in people without an MPN, and venous clot risk remains about three times higher. For a man diagnosed between ages 60 and 69, the five-year chance of a clotting event is roughly 19%, compared to 10% in matched individuals without an MPN. This is why clot prevention, often with low-dose aspirin, is a cornerstone of treatment for most MPN patients.
Progression to More Serious Disease
MPNs can transform into more aggressive conditions over time. The most concerning is progression to acute myeloid leukemia (AML), a fast-moving blood cancer that is much harder to treat. Overall, this happens in about 5 to 10% of MPN patients. The risk varies significantly by type: roughly 20% of myelofibrosis patients will progress within ten years, compared to about 4% of those with polycythemia vera and 1% of those with essential thrombocythemia.
PV and ET can also evolve into myelofibrosis itself, sometimes called “secondary” or “post-PV” and “post-ET” myelofibrosis. This progression involves the gradual scarring of bone marrow that characterizes primary myelofibrosis, and it carries the same complications.
How MPNs Are Treated
Treatment depends on the specific MPN type, the severity of symptoms, and the risk of complications. Many patients with low-risk ET or early PV need only monitoring and low-dose aspirin to reduce clotting risk.
For polycythemia vera, the first-line approach is therapeutic phlebotomy: regular blood draws designed to keep the hematocrit below 45%. This simple intervention meaningfully reduces clot risk by keeping blood from getting too thick. Patients who need frequent phlebotomies or have additional risk factors may also take medication to suppress blood cell production.
For myelofibrosis and symptomatic PV, JAK inhibitor medications have transformed care over the past decade. These drugs work by blocking the overactive JAK signaling pathway that drives the disease. The first, approved in 2011, targets both JAK1 and JAK2 and is effective at shrinking enlarged spleens and reducing symptoms like night sweats, bone pain, and fatigue. Newer options in the same class offer advantages for patients who also have anemia or very low platelet counts, which previously limited treatment options.
The only potentially curative treatment for myelofibrosis is a bone marrow (stem cell) transplant, but it carries significant risks and is generally reserved for younger patients with high-risk disease. For most people, MPN management focuses on controlling symptoms, reducing clot risk, and slowing disease progression.
Living With an MPN
Because MPNs are chronic conditions, most patients live with their diagnosis for many years. Essential thrombocythemia and polycythemia vera in particular have long survival times, and many people maintain active lives with appropriate management. Myelofibrosis carries a more variable outlook depending on the degree of marrow scarring, blood counts, and genetic risk factors.
Regular blood work is a constant in MPN care. Your medical team will monitor blood counts, spleen size, and symptoms over time, adjusting treatment as needed. Changes in fatigue levels, new or worsening symptoms, or shifts in blood counts can signal disease progression and prompt a reassessment of your treatment plan.